43 
research have never been adequately assessed. It is prudent* we be- 
lieve, to proceed with constructive applications of recombinant DNA 
research only when adequate safeguards are provided for. Having 
heard the testimony at the hearings on DNA, and having studied 
this issue for almost a year, we believe the exemption provisions of 
H.R. 11192 do not offer the full protection our environment and 
public health require in a brave new world where corporations can 
now patent new forms of life. 
The attached dissenting views are respectfully submitted to the 
Committee Report on Recombinant DNA by the following members 
of the Interstate and Foreign Commerce Committee who voted against 
reporting H.R. 11192 to the floor of the House : 
Henry A. Waxman. 
Barbara A. Mikulski. 
Andrew Maguire. 
Edward J. Market. 
Marc L. Marks. 
Richard L. Ottinger. 
* 
[Appendix B — 173] 
